{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:05:54Z","timestamp":1792271154999,"version":"4.4.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"vor","delay-in-days":333,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.autrev.2018.10.004","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T09:15:02Z","timestamp":1547198102000},"page":"293-305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":158,"title":["Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays"],"prefix":"10.1016","volume":"18","author":[{"given":"Jan","family":"Damoiseaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Vulsteke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk C.M.","family":"Platteel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Piette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ora","family":"Shovman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien","family":"Bonroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f6rte","family":"Hamann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"De Langhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucille","family":"Musset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bossuyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2018.10.004_bb0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.autrev.2014.01.022","article-title":"Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review","volume":"13","author":"Mahler","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2018.10.004_bb0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.autrev.2018.10.004_bb0020","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40063","article-title":"Editorial: a new classification of adult autoimmune myositis","volume":"69","author":"Sen\u00e9cal","year":"2017","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2018.10.004_bb0025","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/WCO.0000000000000376","article-title":"Advances in serological diagnostics of inflammatory myopathies","volume":"29","author":"Benveniste","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/PLMI.S56781","article-title":"Multiparametric autoimmune diagnostics: recent advances","volume":"8","author":"Damoiseaux","year":"2016","journal-title":"Path. Lab Med. Int."},{"key":"10.1016\/j.autrev.2018.10.004_bb0035","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1515\/cclm-2017-0826","article-title":"EASI \u2013 European Autoimmunity Standardisation Initiative: facing the challenges of diagnostics in autoimmunity","volume":"56","author":"Damoiseaux","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.autrev.2018.10.004_bb0040","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.autrev.2016.09.021","article-title":"Accreditation in autoimmune diagnostic laboratories. A position paper of the European Autoimmunity Standardization Initiative (EASI)","volume":"16","author":"Bizzaro","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2018.10.004_bb0045","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00005792-197707000-00001","article-title":"Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis","volume":"56","author":"Bohan","year":"1977","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2018.10.004_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification of iidiopathic iinflammatory myopathies based on clinic manifestations and myositis-specific autoantibodies","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0055","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"Immune-mediated necrotizing myopathies working group. 224th ENMC international workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.autrev.2018.10.004_bb0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.autrev.2018.10.004_bb0065","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and Juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0070","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2018.10.004_bb0075","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/brain\/awv192","article-title":"Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis","volume":"138","author":"Mescam-Mancini","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2018.10.004_bb0080","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11926-015-0548-6","article-title":"Immune-mediated necrotizing myopathy: update on diagnosis and management","volume":"17","author":"Basharat","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.autrev.2018.10.004_bb0085","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.autrev.2018.10.004_bb0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","article-title":"Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients","volume":"10","author":"Suzuki","year":"2015","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0095","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2018.10.004_bb0100","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2018.10.004_bb0105","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0110","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","article-title":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset","volume":"53","author":"Tansley","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2018.10.004_bb0115","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0090-1229(76)90145-8","article-title":"Description of a serological reaction characteristic of polymyositis","volume":"5","author":"Reichlin","year":"1976","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0120","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/ard.2005.040717","article-title":"Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0125","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","article-title":"The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM","volume":"51","author":"Koga","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2018.10.004_bb0130","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2018.10.004_bb0135","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/acr.21728","article-title":"Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti\u2013melanoma differentiation\u2013associated gene 5 antibody","volume":"64","author":"Cao","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.autrev.2018.10.004_bb0140","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.autrev.2018.10.004_bb0145","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0150","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s10067-015-2928-8","article-title":"Diagnosis and treatment of clinically amyopathic dermatomyositis (CADM): a case series and literature review","volume":"35","author":"Gil","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0155","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"Childhood myositis heterogeneity study group; international myositis collaborative study group. A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2018.10.004_bb0160","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2018.10.004_bb0165","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2018.10.004_bb0170","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2011-200697","article-title":"Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy","volume":"71","author":"Ichimura","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0175","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","article-title":"Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-specific Autoantibodies","volume":"20","author":"Wolstencroft","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.autrev.2018.10.004_bb0180","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/art.1780230802","article-title":"Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system","volume":"23","author":"Nishikai","year":"1980","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.autrev.2018.10.004_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: eterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.autrev.2018.10.004_bb0190","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1183\/09031936.00104310","article-title":"Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies","volume":"37","author":"Hervier","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.autrev.2018.10.004_bb0195","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2018.10.004_bb0200","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0205","first-page":"384","article-title":"Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis","volume":"56","author":"Aggarwal","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2018.10.004_bb0210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","article-title":"Immune-mediated necrotizing myopathy","volume":"20","author":"Pinal-Fernandez","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.autrev.2018.10.004_bb0215","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in anti-SRP+ and antiHMGCR+ myopathies: role of autoantibodies and complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2018.10.004_bb0220","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/ard.2006.052191","article-title":"Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy","volume":"65","author":"Hengstman","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0225","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2018.10.004_bb0230","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in european patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2018.10.004_bb0235","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","article-title":"Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study","volume":"15","author":"Musset","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2018.10.004_bb0240","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutarylcoenzyme a reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2018.10.004_bb0245","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3899\/jrheum.160871","article-title":"Juvenile dermatomyositis research group. Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients","volume":"44","author":"Tansley","year":"2017","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0250","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/annrheumdis-2017-212436","article-title":"Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis","volume":"77","author":"Yeker","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0255","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5\u2032-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0260","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5\u2032-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0265","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2016-210282","article-title":"Cytosolic 5\u2032-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis","volume":"76","author":"Lilleker","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0270","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.autrev.2007.01.013","article-title":"Novel aspects of autoantibodies to the PM\/Scl complex: clinical, genetic and diagnostic insights","volume":"6","author":"Mahler","year":"2007","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2018.10.004_bb0275","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00296-009-0884-9","article-title":"Characteristics of interstitial lung disease in SS-A positive\/Jo-1 positive inflammatory myopathy patients","volume":"29","author":"V\u00e1ncsa","year":"2009","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.autrev.2018.10.004_bb0280","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.autrev.2018.10.004_bb0285","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine"},{"key":"10.1016\/j.autrev.2018.10.004_bb0290","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-212701","article-title":"2017 EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?","volume":"77","author":"Malaviya","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0295","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.autrev.2017.05.003","article-title":"Integrated diagnosis project for inflammatory myopathies: an association between autoantibodies and muscle pathology","volume":"16","author":"Suzuki","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2018.10.004_bb0300","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/ard.2009.127100","article-title":"ANA screening: an old test with new recommendations","volume":"69","author":"Meroni","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0305","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2013-203863","article-title":"International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"73","author":"Agmon-Levin","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0310","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1515\/cclm-2017-0905","article-title":"Screening for connective tissue disease-associated antibodies by automated immunoassay","volume":"56","author":"Willems","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.autrev.2018.10.004_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13317-016-0075-0","article-title":"International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results","volume":"7","author":"Damoiseaux","year":"2016","journal-title":"Auto Immun. Highlights"},{"key":"10.1016\/j.autrev.2018.10.004_bb0320","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3899\/jrheum.160618","article-title":"A negative antinuclear antibody does not indicate autoantibody negativity in myositis: role of anticytoplasmic antibody as a screening test for antisynthetase syndrome","volume":"44","author":"Aggarwal","year":"2017","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0325","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.autrev.2015.01.017","article-title":"Autoantibodies 2015: from diagnostic biomarkers towards prediction, prognosis and prevention","volume":"14","author":"Damoiseaux","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2018.10.004_bb0330","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3899\/jrheum.170258","article-title":"The antinuclear antibody test in the diagnosis of antisynthetase syndrome and other autoimmune myopathies","volume":"45","author":"Fritzler","year":"2018","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0335","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3389\/fimmu.2015.00412","article-title":"Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014\u20132015","volume":"6","author":"Chan","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0340","doi-asserted-by":"crossref","first-page":"405956","DOI":"10.1155\/2014\/405956","article-title":"Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies","volume":"2014","author":"Musset","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.autrev.2018.10.004_bb0345","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s12026-015-8774-6","article-title":"Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study","volume":"64","author":"Picard","year":"2016","journal-title":"Immunol. Res."},{"key":"10.1016\/j.autrev.2018.10.004_bb0350","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-204793","article-title":"Detection of antinuclear antibodies: added value of solid phase assay?","volume":"73","author":"Bossuyt","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0355","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.autrev.2018.03.002","article-title":"Solid phase assays versus automated indirect immunofluorescence for detection of antinuclear antibodies","volume":"17","author":"Claessens","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2018.10.004_bb0360","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.autrev.2011.06.005","article-title":"Detection of antinuclear antibodies by indirect immunofluorescence and by solid phase assay","volume":"10","author":"Op De Beeck","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2018.10.004_bb0365","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1515\/cclm-2013-0211","article-title":"The integration of the detection of systemic sclerosis-associated antibodies in a routine laboratory setting: comparison of different strategies","volume":"51","author":"Bonroy","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.autrev.2018.10.004_bb0370","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.autrev.2016.09.005","article-title":"Statin-associated autoimmune myopathy: a distinct new IFL pattern can increase the rate of HMGCR antibody detection by clinical laboratories","volume":"15","author":"Alvarado-Cardenas","year":"2016","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2018.10.004_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2016.02.017","article-title":"Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera","volume":"433","author":"Cavazzana","year":"2016","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.autrev.2018.10.004_bb0380","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-212786","article-title":"Response to: 'Performance of the 2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practice' by Hocevar et al","author":"Lundberg","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0385","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s13317-014-0059-x","article-title":"Efficiency of a solid-phase chemiluminescence immunoassay for detection of antinuclear and cytoplasmic autoantibodies compared with gold standard immunoprecipitation","volume":"5","author":"Gelpi","year":"2014","journal-title":"Auto Immun. Highlights"},{"key":"10.1016\/j.autrev.2018.10.004_bb0390","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4155\/bio-2016-0252","article-title":"Zenit RA evaluation, a solid-phase chemiluminescence immunoassay for detection of anti-cellular antibodies","volume":"9","author":"Melguizo Madrid","year":"2017","journal-title":"Bioanalysis"},{"key":"10.1016\/j.autrev.2018.10.004_bb0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085062","article-title":"The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia","volume":"9","author":"Nakashima","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.autrev.2018.10.004_bb0400","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jdermsci.2016.09.013","article-title":"Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis","volume":"84","author":"Fujimoto","year":"2016","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.autrev.2018.10.004_bb0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154285","article-title":"Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies","volume":"11","author":"Sato","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.autrev.2018.10.004_bb0410","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0415","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/art.1780330908","article-title":"Antibody to signal recognition particle in polymyositis","volume":"33","author":"Targoff","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2018.10.004_bb0420","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/rheumatology\/keu436","article-title":"Anti-signal recognition particle autoantibody ELISA validation and clinical associations","volume":"54","author":"Aggarwal","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2018.10.004_bb0425","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/acr.20219","article-title":"Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series","volume":"62","author":"Valiyil","year":"2010","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.autrev.2018.10.004_bb0430","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2018.10.004_bb0435","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cca.2017.07.011","article-title":"Detection of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme a reductase by ELISA in a reference laboratory setting","volume":"472","author":"Jaskowski","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.autrev.2018.10.004_bb0440","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12026-016-8867-x","article-title":"Anti-HMGCR antibodies demonstrate high diagnostic value in the diagnosis of immune-mediated necrotizing myopathy following statin exposure","volume":"65","author":"Shovman","year":"2017","journal-title":"Immunol. Res."},{"key":"10.1016\/j.autrev.2018.10.004_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020266","article-title":"Autoantibodies against a 43 kDa muscle protein in inclusion body myositis","volume":"6","author":"Salajegheh","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.autrev.2018.10.004_bb0450","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s13317-016-0088-8","article-title":"Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis","volume":"7","author":"Kramp","year":"2016","journal-title":"Auto Immun. Highlights"},{"key":"10.1016\/j.autrev.2018.10.004_bb0455","first-page":"748","article-title":"Fluoroenzymeimmunoassay to detect systemic sclerosis-associated antibodies: diagnostic performance and correlation with conventional techniques","volume":"30","author":"Bonroy","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0460","doi-asserted-by":"crossref","first-page":"R704","DOI":"10.1186\/ar1729","article-title":"Clinical evaluation of autoantibodies to a novel PM\/Scl peptide antigen","volume":"7","author":"Mahler","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.autrev.2018.10.004_bb0465","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.autrev.2008.12.001","article-title":"PM1-alpha ELISA: the assay of choice for the detection of anti-PM\/Scl autoantibodies?","volume":"8","author":"Mahler","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2018.10.004_bb0470","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/ar2614","article-title":"Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients","volume":"11","author":"Hanke","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.autrev.2018.10.004_bb0475","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fimmu.2015.00181","article-title":"The uses and misuses of multiplex autoantibody assays in systemic autoimmune rheumatic diseases","volume":"6","author":"Satoh","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0480","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211868","article-title":"The EuroMyositis registry: an international collaborative tool to facilitate myositis research","volume":"77","author":"Lilleker","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0485","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.autrev.2009.03.005","article-title":"Use of commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies","volume":"9","author":"R\u00f6nnelid","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2018.10.004_bb0490","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1093\/rheumatology\/keq281","article-title":"Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay","volume":"49","author":"Ghirardello","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2018.10.004_bb0495","doi-asserted-by":"crossref","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","article-title":"Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis","volume":"68","author":"Cruellas","year":"2013","journal-title":"Clinics"},{"key":"10.1016\/j.autrev.2018.10.004_bb0500","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/jcla.21948","article-title":"A new immunodot assay for multiplex detection of autoantibodies in a cohort of Italian patients with idiopathic myopathies","volume":"30","author":"Tampoia","year":"2016","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.autrev.2018.10.004_bb0505","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/1756-185X.12792","article-title":"Test performance of a myositis panel in a clinical immunology laboratory in New South Wales, Australia","volume":"19","author":"Tan","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0510","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.pathol.2016.03.012","article-title":"Diagnostic performance of a commercial immunoblot assay for myositis antibody testing","volume":"48","author":"Bundell","year":"2016","journal-title":"Pathology"},{"key":"10.1016\/j.autrev.2018.10.004_bb0515","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12026-017-8974-3","article-title":"Reflex testing of speckled cytoplasmic patterns observed in routine ANA HEp-2 indirect immunofluorescence with a multiplex anti-synthetase dot-blot assay: a multicentric pilot study","volume":"66","author":"Infantino","year":"2018","journal-title":"Immunol. Res."},{"key":"10.1016\/j.autrev.2018.10.004_bb0520","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/08916934.2018.1441830","article-title":"Clinical contribution of myositis-related antibodies detected by immunoblot to idiopathic inflammatory myositis: a one-year retrospective study","volume":"51","author":"Lecouffe-Desprets","year":"2018","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2018.10.004_bb0525","article-title":"Detection of myositis-specific antibodies","author":"Vulsteke","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0530","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s13075-017-1469-8","article-title":"Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study","volume":"19","author":"Yang","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.autrev.2018.10.004_bb0535","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/jdv.14759","article-title":"Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients","volume":"32","author":"Best","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Vernereol."},{"key":"10.1016\/j.autrev.2018.10.004_bb0540","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00408-018-0108-8","article-title":"Prevalence of myositis-specific antibodies in idiopathic interstitial pneumonias","volume":"196","author":"De Sadeleer","year":"2018","journal-title":"Lung"},{"key":"10.1016\/j.autrev.2018.10.004_bb0545","article-title":"Detection of myositis-specific antibodies: additional notes","author":"Mahler","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0550","article-title":"Response to \u2018detection of myositis-specific antibodies: additional notes\u2019","author":"Infantino","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0555","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.autrev.2009.01.013","article-title":"Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory","volume":"8","author":"Bossuyt","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2018.10.004_bb0560","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1136\/ard.2007.084228","article-title":"Standardisation in clinical laboratory medicine: an ethical reflection","volume":"67","author":"Bossuyt","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2018.10.004_bb0565","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.autrev.2018.03.004","article-title":"Validation conform ISO-15189 of assays in the field of autoimmunity: joint efforts in the Netherlands","volume":"17","author":"Mulder","year":"2018","journal-title":"Autoimmun. Rev."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219300096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997219300096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:15:22Z","timestamp":1761599722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997219300096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":113,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1568997219300096"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2018.10.004","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2018.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}